CLINICAL_TRIALS
trial_result
· 2019-10-29
Clinical Trial Update: Phase 2 Study of Oral IXAZOMIB in Adult Participants With Relapsed and/or Refractory Follicular Lymphoma [Phase 2]
Summary
Phase 2 study of oral ixazomib in adults with relapsed/refractory follicular lymphoma has completed with results posted in 2019.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Follicular Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2019-10-29